This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Inukai, M. Articles by Date, H. Search for Related Content PubMed PubMed Citation Articles by Inukai, M. Articles by Date, H.

Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer

Departments of ¹ Cancer and Thoracic Surgery, ² Molecular Genetics, and ³ Hematology, Oncology, and Respiratory Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan; and ⁴ National Sanyo Hospital Respiratory Disease Center, Ube, Japan

Requests for reprints: Shinichi Toyooka, Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. Phone: 81-86-235-7265; Fax: 81-86-235-7269; E-mail; s_toyooka{at}nigeka2.hospital.okayama-u.ac.jp.

The threonine-to-methionine substitution at amino acid position 790 (T790M) of the epidermal growth factor receptor (EGFR) gene has been reported in progressing lesions after gefitinib treatment in non–small cell lung cancer (NSCLC) that causes sensitive tumors to become resistant to gefitinib. Alternatively, the EGFR T790M mutation might be present in small fractions of tumor cells before drug treatment, and the tumor cells harboring the T790M mutation might be enriched during the proliferation after drug treatment. We developed a mutant-enriched PCR assay to detect small fractions of cells with T790M mutation and used this technique to detect mutations in 280 NSCLCs, including gefitinib-treated 95 cases. Although the direct sequencing detected only 1 T790M mutant case, the mutant-enriched PCR (confirmed to enrich one mutant out of 1 x 10³ wild-type alleles) detected 9 additional cases among 280 cases. As linkage to clinicopathologic factors, the T790M mutation showed no bias for sex, smoking status, or histology but was significantly more frequent in advanced tumors (9 of 111 cases) than in early-stage tumors (1 of 169 cases; P = 0.0013). Among gefitinib-treated cases, gefitinib-sensitive mutations were found in 30 cases. The T790M mutation was present in 3 of 7 no-responders with the gefitinib-sensitive mutation and was not present in 19 responders (P = 0.014). Our results indicate that the T790M mutation is sometimes present in a minor population of tumor cells during the development of NSCLC and suggest that the detection of small fractions of T790M mutant alleles may be useful for predicting gefitinib resistance of NSCLCs with sensitive EGFR mutations. (Cancer Res 2006; 66(16): 7854-8)

This article has been cited by other articles:

				E. Ballatori, S. Fatigoni, F. Roila, B. Seruga, E. Amir, I. Tannock, T. Takano, J. Wang, J.-h. Qiu, T. S. Mok, et al. Treatment of lung cancer. N. Engl. J. Med., December 17, 2009; 361(25): 2485 - 2486. [Full Text] [PDF]

				I. Y.-S. Tam, E. L.-H. Leung, V. P.-C. Tin, D. T.-T. Chua, A. D.-L. Sihoe, L.-C. Cheng, L.-P. Chung, and M. P. Wong Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations Mol. Cancer Ther., August 1, 2009; 8(8): 2142 - 2151. [Abstract] [Full Text] [PDF]

				G. D. Girnun, L. Chen, J. Silvaggi, R. Drapkin, L. R. Chirieac, R. F. Padera, R. Upadhyay, S. B. Vafai, R. Weissleder, U. Mahmood, et al. Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin Clin. Cancer Res., October 15, 2008; 14(20): 6478 - 6486. [Abstract] [Full Text] [PDF]

				R. S. Herbst, J. V. Heymach, and S. M. Lippman Lung Cancer N. Engl. J. Med., September 25, 2008; 359(13): 1367 - 1380. [Full Text] [PDF]

				S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, E. Inserra, S. Diederichs, A. J. Iafrate, D. W. Bell, et al. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells N. Engl. J. Med., July 24, 2008; 359(4): 366 - 377. [Abstract] [Full Text] [PDF]

				C.-H. Yang, C.-J. Yu, J.-Y. Shih, Y.-C. Chang, F.-C. Hu, M.-C. Tsai, K.-Y. Chen, Z.-Z. Lin, C.-J. Huang, C.-T. Shun, et al. Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non-Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy J. Clin. Oncol., June 1, 2008; 26(16): 2745 - 2753. [Abstract] [Full Text] [PDF]

				L. V. Sequist, R. G. Martins, D. Spigel, S. M. Grunberg, A. Spira, P. A. Janne, V. A. Joshi, D. McCollum, T. L. Evans, A. Muzikansky, et al. First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations J. Clin. Oncol., May 20, 2008; 26(15): 2442 - 2449. [Abstract] [Full Text] [PDF]

				S. Toyooka, K. Matsuo, H. Shigematsu, T. Kosaka, M. Tokumo, Y. Yatabe, S. Ichihara, M. Inukai, H. Suehisa, J. Soh, et al. The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non small Cell Lung Cancer Clin. Cancer Res., October 1, 2007; 13(19): 5763 - 5768. [Abstract] [Full Text] [PDF]

				A. Ogino, H. Kitao, S. Hirano, A. Uchida, M. Ishiai, T. Kozuki, N. Takigawa, M. Takata, K. Kiura, and M. Tanimoto Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non Small Cell Lung Cancer Cell Line Cancer Res., August 15, 2007; 67(16): 7807 - 7814. [Abstract] [Full Text] [PDF]

				N. Godin-Heymann, I. Bryant, M. N. Rivera, L. Ulkus, D. W. Bell, D. J. Riese II, J. Settleman, and D. A. Haber Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation Cancer Res., August 1, 2007; 67(15): 7319 - 7326. [Abstract] [Full Text] [PDF]

				T. de La Motte Rouge, L. Galluzzi, K. A. Olaussen, Y. Zermati, E. Tasdemir, T. Robert, H. Ripoche, V. Lazar, P. Dessen, F. Harper, et al. A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non-Small Cell Lung Cancer Cells Resistant to Erlotinib Cancer Res., July 1, 2007; 67(13): 6253 - 6262. [Abstract] [Full Text] [PDF]

				H. Vikis, M. Sato, M. James, D. Wang, Y. Wang, M. Wang, D. Jia, Y. Liu, J. E. Bailey-Wilson, C. I. Amos, et al. EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity Cancer Res., May 15, 2007; 67(10): 4665 - 4670. [Abstract] [Full Text] [PDF]